- Home
- THAR vs ISPC Comparison
THAR vs ISPC Comparison
Compare THAR & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- ISPC
- Stock Information
- Founded
- THAR 2017
- ISPC 2009
- Country
- THAR United States
- ISPC United States
- Employees
- THAR N/A
- ISPC N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- ISPC Precision Instruments
- Sector
- THAR Health Care
- ISPC Health Care
- Exchange
- THAR Nasdaq
- ISPC Nasdaq
- Market Cap
- THAR 4.0M
- ISPC 4.7M
- IPO Year
- THAR 2022
- ISPC 2021
- Fundamental
- Price
- THAR $2.03
- ISPC $2.37
- Analyst Decision
- THAR Strong Buy
- ISPC
- Analyst Count
- THAR 1
- ISPC 0
- Target Price
- THAR $17.00
- ISPC N/A
- AVG Volume (30 Days)
- THAR 47.8K
- ISPC 1.2M
- Earning Date
- THAR 11-07-2024
- ISPC 03-12-2025
- Dividend Yield
- THAR N/A
- ISPC N/A
- EPS Growth
- THAR N/A
- ISPC N/A
- EPS
- THAR N/A
- ISPC N/A
- Revenue
- THAR N/A
- ISPC $10,390,702.00
- Revenue This Year
- THAR N/A
- ISPC $13.82
- Revenue Next Year
- THAR N/A
- ISPC $11.76
- P/E Ratio
- THAR N/A
- ISPC N/A
- Revenue Growth
- THAR N/A
- ISPC 0.74
- 52 Week Low
- THAR $1.84
- ISPC $2.30
- 52 Week High
- THAR $7.71
- ISPC $11.80
- Technical
- Relative Strength Index (RSI)
- THAR 45.25
- ISPC 34.01
- Support Level
- THAR $1.86
- ISPC $2.50
- Resistance Level
- THAR $2.06
- ISPC $2.79
- Average True Range (ATR)
- THAR 0.11
- ISPC 0.28
- MACD
- THAR -0.00
- ISPC 0.02
- Stochastic Oscillator
- THAR 38.64
- ISPC 6.48
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.